Akorn, Inc. (AKRX) Short Interest Update

Akorn, Inc. (NASDAQ:AKRX) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totalling 19,291,494 shares, a growth of 23.6% from the August 15th total of 15,605,371 shares. Based on an average daily volume of 3,412,104 shares, the short-interest ratio is presently 5.7 days. Approximately 20.8% of the company’s shares are short sold.

Several equities research analysts recently commented on AKRX shares. Jefferies Group LLC reissued a “hold” rating and set a $34.00 price objective on shares of Akorn in a research note on Wednesday, July 19th. Royal Bank Of Canada set a $34.00 price objective on shares of Akorn and gave the stock a “hold” rating in a research note on Saturday, May 27th. Piper Jaffray Companies reissued a “hold” rating and set a $34.00 price objective on shares of Akorn in a research note on Thursday, August 10th. BidaskClub lowered shares of Akorn from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, TheStreet lowered shares of Akorn from a “b-” rating to a “c” rating in a research note on Tuesday, August 1st. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $28.56.

Akorn (AKRX) opened at 33.02 on Tuesday. The stock has a market capitalization of $4.12 billion, a PE ratio of 33.35 and a beta of 1.38. Akorn has a one year low of $17.61 and a one year high of $34.00. The firm has a 50-day moving average of $33.02 and a 200 day moving average of $31.37.

In other news, Director Brian Tambi sold 5,165 shares of Akorn stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $33.37, for a total transaction of $172,356.05. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Bruce Kutinsky sold 40,000 shares of Akorn stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $33.46, for a total transaction of $1,338,400.00. Following the sale, the chief operating officer now directly owns 317,480 shares in the company, valued at approximately $10,622,880.80. The disclosure for this sale can be found here. Insiders own 28.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Akorn by 12,960.9% in the 1st quarter. BlackRock Inc. now owns 9,080,983 shares of the company’s stock valued at $218,671,000 after purchasing an additional 9,011,455 shares during the last quarter. Pentwater Capital Management LP purchased a new position in Akorn during the 2nd quarter worth approximately $132,148,000. CNH Partners LLC purchased a new position in Akorn during the 2nd quarter worth approximately $116,243,000. Columbia Wanger Asset Management LLC raised its position in Akorn by 127.5% during the 1st quarter. Columbia Wanger Asset Management LLC now owns 2,682,821 shares of the company’s stock worth $64,602,000 after buying an additional 1,503,366 shares during the last quarter. Finally, FMR LLC raised its position in Akorn by 54.0% during the 1st quarter. FMR LLC now owns 3,560,997 shares of the company’s stock worth $85,748,000 after buying an additional 1,249,329 shares during the last quarter. Institutional investors and hedge funds own 69.54% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Akorn, Inc. (AKRX) Short Interest Update” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/19/akorn-inc-akrx-short-interest-update.html.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply